BACKGROUND: Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome. METHODS: We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in thePravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial (mean follow-up 24 months) to investigate the risk of cardiovascular death or MI associated with MRP-8/14 measured at 30 days after an acute coronary syndrome. RESULTS:Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th, 75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5] mg/L vs 4.0 [1.9, 10.1] mg/L, P = .020). The risk of a recurrent cardiovascular event increased with each increasing quartile of MRP-8/14 (P-trend = 0.007) such that patients with the highest levels had a 2.0-fold increased odds (95% CI 1.1-3.6, P = .029) of a recurrent event after adjusting for standard risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of MRP-8/14 and high-sensitivity C-reactive protein showed significantly increased risk of cardiovascular death or MI compared with patients with the lowest levels of both markers (adjusted odds ratio 2.1, 95% CI 1.2-3.8). CONCLUSIONS: Myeloid-related protein 8/14 may be a useful biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as a novel target for therapeutic intervention.
RCT Entities:
BACKGROUND: Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome. METHODS: We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial (mean follow-up 24 months) to investigate the risk of cardiovascular death or MI associated with MRP-8/14 measured at 30 days after an acute coronary syndrome. RESULTS:Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th, 75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5] mg/L vs 4.0 [1.9, 10.1] mg/L, P = .020). The risk of a recurrent cardiovascular event increased with each increasing quartile of MRP-8/14 (P-trend = 0.007) such that patients with the highest levels had a 2.0-fold increased odds (95% CI 1.1-3.6, P = .029) of a recurrent event after adjusting for standard risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of MRP-8/14 and high-sensitivity C-reactive protein showed significantly increased risk of cardiovascular death or MI compared with patients with the lowest levels of both markers (adjusted odds ratio 2.1, 95% CI 1.2-3.8). CONCLUSIONS: Myeloid-related protein 8/14 may be a useful biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as a novel target for therapeutic intervention.
Authors: Aileen M Healy; Michael D Pickard; Aruna D Pradhan; Yunmei Wang; Zhiping Chen; Kevin Croce; Masashi Sakuma; Can Shi; Alexandre C Zago; Joseph Garasic; Andrew I Damokosh; Tracy L Dowie; Louis Poisson; James Lillie; Peter Libby; Paul M Ridker; Daniel I Simon Journal: Circulation Date: 2006-05-08 Impact factor: 29.690
Authors: Nerea Varo; James A de Lemos; Peter Libby; David A Morrow; Sabina A Murphy; Rebecca Nuzzo; C Michael Gibson; Christopher P Cannon; Eugene Braunwald; Uwe Schönbeck Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Antonino Buffon; Luigi M Biasucci; Giovanna Liuzzo; Giuseppe D'Onofrio; Filippo Crea; Attilio Maseri Journal: N Engl J Med Date: 2002-07-04 Impact factor: 91.245
Authors: Stephan Baldus; Christopher Heeschen; Thomas Meinertz; Andreas M Zeiher; Jason P Eiserich; Thomas Münzel; Maarten L Simoons; Christian W Hamm Journal: Circulation Date: 2003-09-02 Impact factor: 29.690
Authors: Andrei Maiseyeu; Marcus A Badgeley; Thomas Kampfrath; Georgeta Mihai; Jeffrey A Deiuliis; Cuiqing Liu; Qinghua Sun; Sampath Parthasarathy; Daniel I Simon; Kevin Croce; Sanjay Rajagopalan Journal: Arterioscler Thromb Vasc Biol Date: 2012-02-02 Impact factor: 8.311
Authors: Amit N Vora; Marc P Bonaca; Christian T Ruff; Petr Jarolim; Sabina Murphy; Kevin Croce; Marc S Sabatine; Daniel I Simon; David A Morrow Journal: J Thromb Thrombolysis Date: 2012-08 Impact factor: 2.300
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward Journal: JCI Insight Date: 2016-12-08
Authors: Kevin Croce; Huiyun Gao; Yunmei Wang; Toshifumi Mooroka; Masashi Sakuma; Can Shi; Galina K Sukhova; René R S Packard; Nancy Hogg; Peter Libby; Daniel I Simon Journal: Circulation Date: 2009-07-20 Impact factor: 29.690